119 related articles for article (PubMed ID: 37798926)
1. Targeting BRD4 attenuates the stemness and aggressiveness of ameloblastoma.
Xie J; Zhang J; Xiong G; Ouyang S; Yun B; Xu X; Wang W; Zhang M; Xie N; Chen D; Wang C
Oral Dis; 2023 Oct; ():. PubMed ID: 37798926
[TBL] [Abstract][Full Text] [Related]
2. FOSL1 promotes tumor growth and invasion in ameloblastoma.
Xiong G; Ouyang S; Xie N; Xie J; Wang W; Yi C; Zhang M; Xu X; Chen D; Wang C
Front Oncol; 2022; 12():900108. PubMed ID: 36185257
[TBL] [Abstract][Full Text] [Related]
3. ARV-825 Showed Antitumor Activity against BRD4-NUT Fusion Protein by Targeting the BRD4.
Yang L; Jing Y; Xia X; Yin X
J Oncol; 2023; 2023():9904143. PubMed ID: 38130463
[TBL] [Abstract][Full Text] [Related]
4. BRD4 promotes the stemness of gastric cancer cells via attenuating miR-216a-3p-mediated inhibition of Wnt/β-catenin signaling.
Song H; Shi L; Xu Y; Xu T; Fan R; Cao M; Xu W; Song J
Eur J Pharmacol; 2019 Jun; 852():189-197. PubMed ID: 30876979
[TBL] [Abstract][Full Text] [Related]
5. Co-targeting BET bromodomain BRD4 and RAC1 suppresses growth, stemness and tumorigenesis by disrupting the c-MYC-G9a-FTH1axis and downregulating HDAC1 in molecular subtypes of breast cancer.
Ali A; Shafarin J; Unnikannan H; Al-Jabi N; Jabal RA; Bajbouj K; Muhammad JS; Hamad M
Int J Biol Sci; 2021; 17(15):4474-4492. PubMed ID: 34803511
[TBL] [Abstract][Full Text] [Related]
6. The CDK4/6-UCHL5-BRD4 axis confers resistance to BET inhibitors in MLL-rearranged leukemia cells by suppressing BRD4 protein degradation.
Amari K; Sasagawa S; Imayoshi N; Toda Y; Hosogi S; Imamura T; Ashihara E
Biochem Biophys Res Commun; 2022 Jan; 588():147-153. PubMed ID: 34954522
[TBL] [Abstract][Full Text] [Related]
7. Breaking boundaries: Pan BETi disrupt 3D chromatin structure, BD2-selective BETi are strictly epigenetic transcriptional regulators.
Tsujikawa LM; Kharenko OA; Stotz SC; Rakai BD; Sarsons CD; Gilham D; Wasiak S; Fu L; Sweeney M; Johansson JO; Wong NCW; Kulikowski E
Biomed Pharmacother; 2022 Aug; 152():113230. PubMed ID: 35687908
[TBL] [Abstract][Full Text] [Related]
8. Concurrent targeting of MAP3K3 and BRD4 by
Liu C; Gen Y; Tanimoto K; Muramatsu T; Inoue J; Inazawa J
Mol Ther Nucleic Acids; 2021 Sep; 25():83-92. PubMed ID: 34258104
[TBL] [Abstract][Full Text] [Related]
9. BRD4 PROTAC degrader ARV-825 inhibits T-cell acute lymphoblastic leukemia by targeting 'Undruggable' Myc-pathway genes.
Wu S; Jiang Y; Hong Y; Chu X; Zhang Z; Tao Y; Fan Z; Bai Z; Li X; Chen Y; Li Z; Ding X; Lv H; Du X; Lim SL; Zhang Y; Huang S; Lu J; Pan J; Hu S
Cancer Cell Int; 2021 Apr; 21(1):230. PubMed ID: 33888130
[TBL] [Abstract][Full Text] [Related]
10. Caveolin-2 is regulated by BRD4 and contributes to cell growth in pancreatic cancer.
Jiao F; Han T; Yuan C; Liang Y; Cui J; Zhuo M; Wang L
Cancer Cell Int; 2020; 20():55. PubMed ID: 32099528
[TBL] [Abstract][Full Text] [Related]
11. Bromodomain-Containing Protein BRD4 Is Hyperphosphorylated in Mitosis.
Wang R; Yang JF; Ho F; Robertson ES; You J
Cancers (Basel); 2020 Jun; 12(6):. PubMed ID: 32575711
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic Targeting of BRD4 in Head Neck Squamous Cell Carcinoma.
Wu Y; Wang Y; Diao P; Zhang W; Li J; Ge H; Song Y; Li Z; Wang D; Liu L; Jiang H; Cheng J
Theranostics; 2019; 9(6):1777-1793. PubMed ID: 31037138
[TBL] [Abstract][Full Text] [Related]
13. Targeting Bromodomain and Extra-Terminal (BET) Family Proteins in Castration-Resistant Prostate Cancer (CRPC).
Welti J; Sharp A; Yuan W; Dolling D; Nava Rodrigues D; Figueiredo I; Gil V; Neeb A; Clarke M; Seed G; Crespo M; Sumanasuriya S; Ning J; Knight E; Francis JC; Hughes A; Halsey WS; Paschalis A; Mani RS; Raj GV; Plymate SR; Carreira S; Boysen G; Chinnaiyan AM; Swain A; de Bono JS;
Clin Cancer Res; 2018 Jul; 24(13):3149-3162. PubMed ID: 29555663
[No Abstract] [Full Text] [Related]
14. BRD4 promotes glioma cell stemness via enhancing miR-142-5p-mediated activation of Wnt/β-catenin signaling.
Wang J; Quan Y; Lv J; Gong S; Dong D
Environ Toxicol; 2020 Mar; 35(3):368-376. PubMed ID: 31724259
[TBL] [Abstract][Full Text] [Related]
15. Tumoral BRD4 expression in lymph node-negative breast cancer: association with T-bet+ tumor-infiltrating lymphocytes and disease-free survival.
Lee M; Tayyari F; Pinnaduwage D; Bayani J; Bartlett JMS; Mulligan AM; Bull SB; Andrulis IL
BMC Cancer; 2018 Jul; 18(1):750. PubMed ID: 30029633
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive analysis of the prognosis and immune infiltrates for the BET protein family reveals the significance of BRD4 in glioblastoma multiforme.
Ye Y; Zhong W; Qian J; Zhang J; Xu T; Han R; Han J; Wang C; Song L; Zeng X; Wang H
Front Cell Dev Biol; 2023; 11():1042490. PubMed ID: 36711038
[No Abstract] [Full Text] [Related]
17. BET Inhibitors Potentiate Chemotherapy and Killing of
Tan X; Tong J; Wang YJ; Fletcher R; Schoen RE; Yu J; Shen L; Zhang L
Cancer Res; 2019 Mar; 79(6):1191-1203. PubMed ID: 30674532
[TBL] [Abstract][Full Text] [Related]
18. Selective N-Terminal BET Bromodomain Inhibitors by Targeting Non-Conserved Residues and Structured Water Displacement*.
Cui H; Divakaran A; Pandey AK; Johnson JA; Zahid H; Hoell ZJ; Ellingson MO; Shi K; Aihara H; Harki DA; Pomerantz WCK
Angew Chem Int Ed Engl; 2021 Jan; 60(3):1220-1226. PubMed ID: 32975004
[TBL] [Abstract][Full Text] [Related]
19. LGR5
Chang TH; Shanti RM; Liang Y; Zeng J; Shi S; Alawi F; Carrasco L; Zhang Q; Le AD
Cell Death Dis; 2020 May; 11(5):338. PubMed ID: 32382005
[TBL] [Abstract][Full Text] [Related]
20. p113 isoform encoded by CUX1 circular RNA drives tumor progression via facilitating ZRF1/BRD4 transactivation.
Yang F; Hu A; Guo Y; Wang J; Li D; Wang X; Jin S; Yuan B; Cai S; Zhou Y; Li Q; Chen G; Gao H; Zheng L; Tong Q
Mol Cancer; 2021 Sep; 20(1):123. PubMed ID: 34579723
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
